Dianthus Therapeutics (NASDAQ: DNTH) net income
Dianthus Therapeutics reported a net loss of $162.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $85.0m. Earnings per share were −$4.20.
Dianthus Therapeutics's best year of the last 9 was fiscal 2022. It reported a loss in 9 of those 9 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$162.3m | — | −1,007.1% | −$4.20 |
| 2024 | −$85.0m | — | −489.3% | −$2.55 |
| 2023 | −$43.6m | — | −914.3% | −$8.45 |
| 2022 | −$28.5m | — | — | −$32.57 |
| 2021 | −$71.1m | — | — | −$1.29 |
| 2020 | −$74.9m | — | — | −$1.71 |
| 2019 | −$76.8m | — | — | — |
| 2018 | −$57.5m | — | — | — |
| 2017 | −$35.5m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Dianthus Therapeutics net income compared with its sector
By net income for its latest fiscal year, Dianthus Therapeutics ranks 390th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Dianthus Therapeutics, −1,007.1%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 388th | CG Oncology | −$161.0m | −3,985.0% |
| 389th | Kyverna Therapeutics | −$161.3m | — |
| 390th | Dianthus Therapeutics | −$162.3m | −1,007.1% |
| 391st | Olema Pharmaceuticals | −$162.5m | — |
| 392nd | Nektar Therapeutics | −$164.1m | −297.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Dianthus Therapeutics
- How much did Dianthus Therapeutics earn in fiscal 2025?
- Dianthus Therapeutics reported a net loss of $162.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $85.0m.
- What are the earnings per share of Dianthus Therapeutics?
- They were −$4.20 in fiscal 2025, compared with −$2.55 in fiscal 2024.
- Where does Dianthus Therapeutics rank in its sector by net income?
- It ranks 390th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Dianthus Therapeutics come from?
- From the annual report (Form 10-K) that Dianthus Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Dianthus Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Dianthus Therapeutics: the Dianthus Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.